Refine
Has Fulltext
- yes (13)
Is part of the Bibliography
- yes (13)
Year of publication
- 2019 (13) (remove)
Document Type
- Journal article (7)
- Doctoral Thesis (6)
Keywords
- Phosphoglykolatphosphatase (2)
- cisplatin (2)
- vitamin B6 (2)
- Aldosteron (1)
- Aneugene (1)
- Antioxidans (1)
- Biomarker (1)
- CFP (1)
- Cytologie (1)
- ERK signaling (1)
- ERK1/2 (1)
- Epac (1)
- FRET (1)
- Flugzeitmassenspektrometrie (1)
- Genotoxicitiy (1)
- Genotoxizität (1)
- Glycerin-3-phosphat (1)
- Glycerinphosphate (1)
- HIPEC therapy (1)
- HeLa cells (1)
- Hypernephrom (1)
- Hyperthermie (1)
- Klassifizierung (1)
- Klastogene (1)
- Lipidom (1)
- Lipidomics (1)
- Maus (1)
- Oxidativer Stress (1)
- PDE-Hemmung (1)
- Phosphatase (1)
- Phosphatasen (1)
- Phosphodiesterasen (1)
- Phosphoglykolat (1)
- Phosphoglykolat-Phosphatase (1)
- Physiologie (1)
- Spironolacton (1)
- Sulfonylharnstoffe (1)
- Sulforaphan (1)
- Sulforaphane (1)
- Time-of-flight (1)
- YFP (1)
- actin cytoskeleton (1)
- aneugens (1)
- aortocaval fistula model (1)
- apoptosis (1)
- biological techniques (1)
- biomarker (1)
- biosensor (1)
- cAMP (1)
- cancer (1)
- cardiac remodelling (1)
- cell signalling (1)
- classification (1)
- clastogens (1)
- comet assay (1)
- eccentric hypertrophy (1)
- efficient intervention points (1)
- eugenol (1)
- gastrointestinal cancer (1)
- hA<sub>3</sub>AR (1)
- haloacid dehalogenase-type phosphatase (1)
- indolylpyrimidylpiperazines (1)
- major depression (1)
- metabolism (1)
- micronucleus test (1)
- mitotic catastrophe (1)
- motor performance (1)
- neuropsychiatric diseases (1)
- neurotransmitter biosynthesis (1)
- optimal drug combination (1)
- optimal drug targeting (1)
- optimal pharmacological modulation (1)
- optimal treatment strategies (1)
- partial agonists (1)
- phosphorylation (1)
- pyridoxal phosphatase (1)
- radiation (1)
- sulfonylurea (1)
- volume overload (1)
- γ-Aminobutyric acid (GABA) (1)
Institute
- Institut für Pharmakologie und Toxikologie (13) (remove)
Mammalian haloacid dehalogenase (HAD)-type phosphatases have evolved to dephosphorylate a wide range of small metabolites, but can also target macromolecules such as serine/threonine, tyrosine-, and histidine-phosphorylated proteins. To accomplish these tasks, HAD phosphatases are equipped with cap domains that control access to the active site and provide substrate specificity determinants. A number of capped HAD phosphatases impact protein phosphorylation, although structural data are consistent with small metabolite substrates rather than protein substrates. This review discusses the structures, functions and disease implications of the three closely related, capped HAD phosphatases pyridoxal phosphatase (PDXP or chronophin), phosphoglycolate phosphatase (PGP, also termed AUM or glycerol phosphatase) and phospholysine phosphohistidine inorganic pyrophosphate phosphatase (LHPP or HDHD2B). Evidence in support of small metabolite and protein phosphatase activity is discussed in the context of the diversity of their biological functions.